Severe Alopecia Areata Treatment Approved by FDA

Deuruxolitinib tablets, weighing eight milligrammes, have been authorised by the FDA to treat people suffering from severe alopecia areata. Approved based on outcomes from two multicenter phase 3 clinical studies (THRIVE-AA1 and THRIVE-AA2) that evaluated deuruxolitinib usage in patients with alopecia areata who had at least 50% scalp hair loss.

The authors of the research state that deuruxolitinib, an oral specific inhibitor of Janus Kinases (JAK), JAK1 and JAK2, can interfere with the pathways associated with the effect of loss of hair in severe alopecia areata. Deuruxolitinib is taken twice daily.

The most frequent side effects of deuruxolitinib treatment were nasopharyngitis, acne, and headache. Nevertheless, as described by the research authors, major side effects may involve thrombosis, gastrointestinal perforations, malignancies and acute infections.

Abhay Gandhi, CEO, North America Business, Sun Pharma stated: “Leqselvi offers a new and effective solution that will significantly enhance options for long-suffering patients battling severe alopecia areata and their physicians.”

They continued: “Our fast-growing dermatology business is excited to add this novel treatment to its portfolio.”